Oruka Therapeutics, Inc. (ORKA NASDAQ) stock market data APIs
$26.9514
-0.61(-2.3%)
as of November 14, 2025
Try our APIs with
free plan!
Oruka Therapeutics, Inc. Financial Data Overview
Price chart is built with
Anychart
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Prev. Close
26.9514
Open
26.338
High
27.7163
Low
25.8653
52 wk Range
5.49-29.98
Market Cap
1 311 M
Shares Outstanding
48 409 K
EPS
-0.55
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Oruka Therapeutics, Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Oruka Therapeutics, Inc. data using free add-ons & libraries
Get Oruka Therapeutics, Inc. Fundamental Data
Oruka Therapeutics, Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -125 002 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-09-30
- EPS/Forecast: -0.524
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Oruka Therapeutics, Inc. News
New
Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash and equivalents provides runway over one year past thre...
Oruka Therapeutics to Present at Multiple November Investor Conferences
MENLO PARK, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new ...
Barclays initiates coverage on U.S. small & mid-cap biotech stocks
Investing.com -- Momentum in small and mid-cap (SMID) biotechnology has accelerated recently, with investors rewarding companies bringing new mechanisms and dosing advantages to market. Over the past...
Oruka Therapeutics files to sell 39.43M shares of common stock for holders
* Oruka Therapeutics (NASDAQ:ORKA [https://seekingalpha.com/symbol/ORKA]) has filed to sell 39,425,806 shares of common stock for holders. * This prospectus is not an offer to sell these securitie...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
